Piper Sandler raised the firm’s price target on Edgewise Therapeutics to $51 from $48 and keeps an Overweight rating on the shares. Into the 12-month Phase 2 CANYON data in December, the analyst thinks Becker muscular dystrophy “represents a free call option investors aren’t recognizing.” Street expectations are low, but even if sevasemten shows statistical significance on creatine kinase with directional North Star Ambulatory Assessment trends, this could potentially support a case for accelerated approval filing to drive positive stock movement, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Largest borrow rate increases among liquid names
- Edgewise Therapeutics put volume heavy and directionally bearish
- Edgewise Therapeutics price target raised to $42 from $32 at RBC Capital
- Edgewise Therapeutics price target raised to $42 from $32 at Leerink
- Playtika to acquire SuperPlay, Intel says not selling Mobileye: Morning Buzz